TLSA vs. PGEN, TNGX, TRVI, BTMD, SNDL, CMRX, YMAB, VYGR, LFVN, and ITOS
Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Precigen (PGEN), Tango Therapeutics (TNGX), Trevi Therapeutics (TRVI), biote (BTMD), SNDL (SNDL), Chimerix (CMRX), Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), LifeVantage (LFVN), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry.
Tiziana Life Sciences vs.
Precigen (NASDAQ:PGEN) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.
33.5% of Precigen shares are held by institutional investors. 44.9% of Precigen shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Precigen has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
Precigen presently has a consensus target price of $6.33, indicating a potential upside of 417.01%. Given Precigen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Precigen is more favorable than Tiziana Life Sciences.
Precigen received 339 more outperform votes than Tiziana Life Sciences when rated by MarketBeat users. Likewise, 67.34% of users gave Precigen an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote.
In the previous week, Precigen had 5 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 5 mentions for Precigen and 0 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.47 beat Precigen's score of 0.45 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.
Tiziana Life Sciences has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Tiziana Life Sciences' return on equity of 0.00% beat Precigen's return on equity.
Tiziana Life Sciences has lower revenue, but higher earnings than Precigen.
Summary
Precigen beats Tiziana Life Sciences on 10 of the 15 factors compared between the two stocks.
Get Tiziana Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tiziana Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:TLSA) was last updated on 1/21/2025 by MarketBeat.com Staff
Free TLSA Stock Alerts